Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q3 2020 · 10-Q
Revenue$8.48M$8.48M−7.3% vs Q3 2019 Net Income-$961.17K-$961.17KN/M vs Q3 2019 EPS Diluted-$0.20-$0.20N/M vs Q3 2019 Gross Profit$1,887,497−0.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Operating Cash Flowderived-$994,169N/M Margins · derivedGross margin22.3%+1.5 pt vs Q3 2019
Operating margin-13.2%+3.9 pt vs Q3 2019
Net margin-11.3%−11.8 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 16, 2020 · 47 d after period end